Abstract
Adult T-cell leukemia (ATL) is a severe chemotherapy-resistant malignancy associated with prolonged infection by the human T cell-lymphotropic virus 1 (HTLV-1). One approach to prevent the onset of ATL is to inhibit the growth/transmission of HTLV-1 infected cells using arsenic trioxide (As 2O3). However, there are no reports on the transmission inhibitory effect of As2O3. In this study, we reveal that As2O3 exerts an inhibitory effect on syncytium formation between HTLV-1 infected MT-2 and HeLa cells. In addition, Western blot analysis revealed that the HTLV-1 derived envelope protein gp46 was down regulated by As2O3 treatment, suggesting that As2O 3 may inhibit HTLV-1 virus transmission via down-regulation of gp46. These results suggest that As2O3 may be a promising drug to treat refractory HTLV-1-related diseases. © 2009 Pharmaceutical Society of Japan.
Author supplied keywords
Cite
CITATION STYLE
Nabeshi, H., Yoshikawa, T., Kamada, H., Shibata, H., Sugita, T., Abe, Y., … Tsutsumi, Y. (2009). Arsenic trioxide inhibits human T cell-lymphotropic virus-1-induced syncytiums by down-regulating gp46. Biological and Pharmaceutical Bulletin, 32(7), 1286–1288. https://doi.org/10.1248/bpb.32.1286
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.